{"id":575797,"date":"2025-04-23T00:00:00","date_gmt":"2025-04-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0004-biopharma-dry-age-related-macular-degeneration-epidemiology-mature-markets\/"},"modified":"2026-04-14T10:12:46","modified_gmt":"2026-04-14T10:12:46","slug":"epidop0004-biopharma-dry-age-related-macular-degeneration-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidop0004-biopharma-dry-age-related-macular-degeneration-epidemiology-mature-markets\/","title":{"rendered":"Dry Age-Related Macular Degeneration &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of dry age-related macular degeneration comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of dry age-related macular degeneration for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology&#8217;s diabetic macular edema forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with dry age-related macular degeneration, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with dry age-related macular degeneration, how many in each country across the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dry age-related macular degeneration over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts nine dry age-related macular degeneration patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of dry <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Total prevalent cases of dry <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> without co-existing wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Total prevalent cases of mixed <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Total prevalent cases of fovea-involved dry <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Total prevalent cases of non-fovea-involved dry <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Diagnosed prevalent cases of dry <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Undiagnosed prevalent cases of dry <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Diagnosed drug-treated prevalent <span prevalent cases>cases <\/span>of dry <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<li>Diagnosed non-drug-treated prevalent\u00a0<span prevalent cases>cases <\/span>of dry <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr><\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-575797","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575797\/revisions"}],"predecessor-version":[{"id":577520,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/575797\/revisions\/577520"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=575797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}